| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762556121P | 2017-09-08 | 2017-09-08 | |
| US201862712531P | 2018-07-31 | 2018-07-31 | |
| PCT/US2018/049842WO2019051155A1 (en) | 2017-09-08 | 2018-09-07 | Compounds, compositions and methods for treating or preventing her-driven drug-resistant cancers |
| Publication Number | Publication Date |
|---|---|
| SG11202002060XAtrue SG11202002060XA (en) | 2020-04-29 |
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202002060XASG11202002060XA (en) | 2017-09-08 | 2018-09-07 | Compounds, compositions and methods for treating or preventing her-driven drug-resistant cancers |
| Country | Link |
|---|---|
| US (1) | US11426409B2 (en) |
| EP (1) | EP3679063A4 (en) |
| JP (1) | JP2020533298A (en) |
| KR (1) | KR20200072478A (en) |
| CN (1) | CN111527103A (en) |
| AU (1) | AU2018330171A1 (en) |
| CA (1) | CA3074017A1 (en) |
| IL (1) | IL272844A (en) |
| SG (1) | SG11202002060XA (en) |
| WO (1) | WO2019051155A1 (en) |
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2021536507A (en)* | 2018-09-04 | 2021-12-27 | レイン セラピューティクス インコーポレイティド | Compounds, Compositions, and Methods for Treating or Preventing HER-Driven Cancer |
| US20220194940A1 (en)* | 2019-04-25 | 2022-06-23 | Board Of Regents, The University Of Texas System | Heterocyclic inhibitors of tyrosine kinase |
| GB201913079D0 (en) | 2019-09-11 | 2019-10-23 | Hummingbird Bioscience Holdings Pte Ltd | Treatment and prevention of cancer using her3 antigen-binding molecules |
| EP4096789A4 (en)* | 2020-01-29 | 2023-10-11 | Board of Regents, The University of Texas System | USE OF POZIOTINIB TO TREAT CANCER WITH NRG1 FUSIONS |
| KR20220133927A (en)* | 2020-01-29 | 2022-10-05 | 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 | Use of quinazoline-based tyrosine kinase inhibitors for the treatment of cancers with NRG1 fusions |
| KR20240012522A (en)* | 2021-05-24 | 2024-01-29 | 다이호야쿠힌고교 가부시키가이샤 | Methods of treating subjects with cancer having abnormalities in EGFR and/or HER2 |
| US20250305053A1 (en)* | 2021-06-03 | 2025-10-02 | Merus N.V. | New nrg1 fusions, fusion junctions and methods for detecting them |
| EP4347892A2 (en)* | 2021-06-03 | 2024-04-10 | Merus N.V. | Liquid biopsy assays for detecting nrg1 fusion polynucleotides |
| GB202108449D0 (en) | 2021-06-14 | 2021-07-28 | Hummingbird Bioscience Holdings Pte Ltd | Cells expressing her3 antigen-binding molecules |
| TW202328191A (en) | 2021-09-03 | 2023-07-16 | 英商癌症研究科技有限公司 | Treatment and prevention of cancer using her3 antigen-binding molecules |
| WO2024121163A1 (en) | 2022-12-06 | 2024-06-13 | Cancer Research Technology Limited | Combination of 10d1f and an androgen inhibitor for treatment and prevention of cancers |
| AU2023389035A1 (en) | 2022-12-07 | 2025-07-10 | Hummingbird Bioscience Pte. Ltd. | Combination for treatment and prevention of cancer |
| US20240238439A1 (en) | 2023-01-03 | 2024-07-18 | Hummingbird Bioscience Pte. Ltd. | Her3-binding antibody-drug conjugate |
| WO2024208881A1 (en) | 2023-04-06 | 2024-10-10 | Hummingbird Bioscience Pte. Ltd. | Treatment and prevention of cancer using her3 antigen-binding molecules |
| WO2024213745A1 (en) | 2023-04-14 | 2024-10-17 | Hummingbird Bioscience Pte. Ltd. | Combination for treatment and prevention of cancer |
| WO2025056781A1 (en) | 2023-09-15 | 2025-03-20 | Hummingbird Bioscience Pte. Ltd. | Treatment and prevention of cancer using her3-binding molecules |
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5007790A (en) | 1989-04-11 | 1991-04-16 | Depomed Systems, Inc. | Sustained-release oral drug dosage form |
| US5582837A (en) | 1992-03-25 | 1996-12-10 | Depomed, Inc. | Alkyl-substituted cellulose-based sustained-release oral drug dosage forms |
| WO1997047285A1 (en) | 1996-06-10 | 1997-12-18 | Depomed, Inc. | Gastric-retentive oral controlled drug delivery system with enhanced retention properties |
| US5972389A (en) | 1996-09-19 | 1999-10-26 | Depomed, Inc. | Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter |
| US6635280B2 (en) | 1997-06-06 | 2003-10-21 | Depomed, Inc. | Extending the duration of drug release within the stomach during the fed mode |
| JP4083818B2 (en) | 1997-06-06 | 2008-04-30 | ディポメド，インコーポレイティド | Gastric retentive oral drug dosage form for controlled release of highly soluble drugs |
| JP2004510687A (en) | 1999-11-02 | 2004-04-08 | ディポメド，インコーポレイティド | Pharmacological induction of delivery mode for enhanced gastric drug administration |
| AU767812B2 (en) | 2000-02-04 | 2003-11-27 | Depomed, Inc. | Shell-and-core dosage form approaching zero-order drug release |
| US6488962B1 (en) | 2000-06-20 | 2002-12-03 | Depomed, Inc. | Tablet shapes to enhance gastric retention of swellable controlled-release oral dosage forms |
| US6451808B1 (en) | 2000-10-17 | 2002-09-17 | Depomed, Inc. | Inhibition of emetic effect of metformin with 5-HT3 receptor antagonists |
| EP1401423A4 (en) | 2001-05-29 | 2006-08-16 | Depomed Dev Ltd | Method of treating gastroesophageal reflux disease and nocturnal acid breakthrough |
| WO2003035039A1 (en) | 2001-10-25 | 2003-05-01 | Depomed, Inc. | Methods of treatment using a gastric retained losartan dosage |
| US6723340B2 (en) | 2001-10-25 | 2004-04-20 | Depomed, Inc. | Optimal polymer mixtures for gastric retentive tablets |
| US20030091630A1 (en) | 2001-10-25 | 2003-05-15 | Jenny Louie-Helm | Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data |
| CA2409552A1 (en) | 2001-10-25 | 2003-04-25 | Depomed, Inc. | Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract |
| TWI312285B (en) | 2001-10-25 | 2009-07-21 | Depomed Inc | Methods of treatment using a gastric retained gabapentin dosage |
| US6682759B2 (en) | 2002-02-01 | 2004-01-27 | Depomed, Inc. | Manufacture of oral dosage forms delivering both immediate-release and sustained-release drugs |
| CN101516376A (en)* | 2006-09-18 | 2009-08-26 | 贝林格尔.英格海姆国际有限公司 | Methods for treating cancers carrying EGFR mutations |
| CA2663599A1 (en)* | 2006-09-18 | 2008-03-27 | Boehringer Ingelheim International Gmbh | Method for treating cancer harboring egfr mutations |
| JP5793428B2 (en) | 2009-03-11 | 2015-10-14 | オークランド ユニサーヴィスィズ リミテッド | Prodrug form of kinase inhibitors and their use in therapy |
| MX336332B (en)* | 2009-09-02 | 2016-01-15 | Auckland Uniservices Ltd | Kinase inhibitors, prodrug forms thereof and their use in therapy. |
| TWI405566B (en)* | 2010-02-11 | 2013-08-21 | Univ Nat Taiwan | Use of curcumin or its analogues in cancer therapy utilizing epidermal growth factor receptor tyrosine kinase inhibitor |
| EA201390550A1 (en)* | 2010-10-14 | 2013-08-30 | Ариад Фармасьютикалз, Инк. | METHODS OF INHIBITING PROLIFERATION OF CELLS IN EGFR-STIMULATED MALIGNANT TUMORS |
| DE102011111758A1 (en)* | 2011-08-24 | 2013-02-28 | Dürr Systems GmbH | Control method for a robot |
| EP3226869A4 (en)* | 2014-12-03 | 2018-07-18 | Auckland UniServices, Ltd. | Kinase inhibitor prodrug for the treatment of cancer |
| US10881664B2 (en)* | 2015-05-15 | 2021-01-05 | Novartis Ag | Methods for treating EGFR mutant cancers |
| AU2017363199B2 (en)* | 2016-11-17 | 2023-08-17 | Board Of Regents, The University Of Texas System | Compounds with anti-tumor activity against cancer cells bearing EGFR or HER2 exon 20 mutations |
| Publication number | Publication date |
|---|---|
| AU2018330171A1 (en) | 2020-03-12 |
| CA3074017A1 (en) | 2019-03-14 |
| EP3679063A4 (en) | 2021-06-02 |
| US11426409B2 (en) | 2022-08-30 |
| CN111527103A (en) | 2020-08-11 |
| JP2020533298A (en) | 2020-11-19 |
| IL272844A (en) | 2020-04-30 |
| KR20200072478A (en) | 2020-06-22 |
| WO2019051155A1 (en) | 2019-03-14 |
| EP3679063A1 (en) | 2020-07-15 |
| US20200268759A1 (en) | 2020-08-27 |
| Publication | Publication Date | Title |
|---|---|---|
| IL272844A (en) | Compounds, compositions and methods for treating or preventing her-driven drug-resistant cancers | |
| IL267247B (en) | Compositions and methods for treating cancer | |
| IL264034A (en) | Crispr/cas9-based compositions and methods for treating cancer | |
| IL304820A (en) | Compositions and methods for treating cancer | |
| IL266053A (en) | Compositions and methods for treating ezh2-mediated cancer | |
| SG11202000532SA (en) | Compounds, compositions and methods | |
| AU2022231657A1 (en) | Compositions and Methods for Treating Cancer | |
| PL3676297T3 (en) | Compounds, compositions and methods | |
| IL269620A (en) | Compositions and methods for treating phenylketonuria | |
| IL274837A (en) | Methods and compositions for treating cancers | |
| IL256523A (en) | Compositions and methods for treating cancer | |
| IL263697A (en) | Compounds, compositions and methods for prevention and/or treatment of cancer | |
| IL271256A (en) | Compositions and methods for treating tauopathies | |
| ZA202204657B (en) | Compounds, compositions, and methods for treating t-cell acute lymphoblastic leukemia | |
| PT3552017T (en) | Compounds, compositions and methods | |
| EP3847283A4 (en) | Compounds, compositions and methods for treating or preventing her-driven cancers | |
| EP3638293A4 (en) | Methods and compositions for treating cancer | |
| IL255638A (en) | Compositions and methods for treating cancer | |
| IL270505B1 (en) | Compounds, compositions and methods | |
| SG10202013112YA (en) | Zinc-gamma-pga compositions and methods for treating cancer | |
| EP3714043A4 (en) | Compositions and methods for treating cancer | |
| IL272782A (en) | Compositions and methods for treating cancer | |
| EP3365336A4 (en) | Deuterated compounds for treating hematologic malignancies, and compositions and methods thereof | |
| IL282692A (en) | Madrasin-derivative compounds, composition and uses thereof for treating cancer | |
| ZA201802268B (en) | Methods and compositions for preventing or treating cancer |